US FDA declines to approve Cingulate's ADHD drug
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing